Successful Use of Human AB Serum to Support the Expansion of Adipose Tissue-Derived Mesenchymal Stem/Stromal Cell in a Microcarrier-Based Platform
Mesenchymal stem/stromal cells (MSC) are promising candidates for cell-based therapies and for the promotion of tissue repair, hence the increase of clinical trials in a worldwide scale. In particular, adipose tissue-derived stem/stromal cells (AT MSC) present easy accessibility and a rather straightforward process of isolation, providing a clear advantage over other sources. The high demand of cell doses (millions of cells/kg), needed for infusion in clinical settings, requires a scalable and efficient manufacturing of AT MSC under xenogeneic(xeno)-free culture conditions. Here we describe the successful use of human AB serum [10%(v/v)] as a culture supplement, as well as coating substrate for the expansion of these cells in microcarriers using (i) a spinner flask and (ii) a 500-mL mini-bioreactor (ApplikonTM Biotechnology). Cells were characterized by immunophenotype and multilineage differentiation potential. Upon an initial cell adhesion in the spinner flask of 35 ± 2.5%, culture reached a maximal cell density of 2.6 ± 0.1 × 105 at day 7, obtaining a 15 ± 1-fold increase. The implementation of the culture in the 500-mL mini-bioreactor presented an initial cell adhesion of 22 ± 5%, but it reached maximal cell density of 2.7 ± 0.4 × 105 at day 7, obtaining a 27 ± 8-fold increase. Importantly, in both stirred systems, cells retained their immunophenotype and multilineage differentiation potential (osteo-, chondro- and adipogenic lineages). Overall, the scalability of this microcarrier-based system presented herein is of major importance for the purpose of achieving clinically meaningful cell numbers.
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.1002/c.68
- https://doi.org//10.1007/s00005-016-0394-x
- https://doi.org//10.4252/wjsc.v12.i1.1
- https://doi.org//10.2174/157488807782793763
- https://doi.org//10.1002/stem.139
- https://doi.org//10.1016/j.colsurfb.2017.04.015
- https://doi.org//10.1016/b978-0-12-381422-7.10014-8
- https://doi.org//10.1002/sctm.17-0051
- https://doi.org//10.1016/S1471-4914(01)02016-0
- https://doi.org//10.1002/biot.201400586
- https://doi.org//10.3727/096368910X536473
- https://doi.org//10.1002/biot.201200373
- https://doi.org//10.1089/ten.tec.2011.0255
- https://doi.org//10.1159/000448196
SHARE
Usage metrics
![Frontiers in Bioengineering and Biotechnology](https://s3-eu-west-1.amazonaws.com/876az-branding-figshare/frontiers/logo.png)
AUTHORS (7)
CATEGORIES
- Bioprocessing, Bioproduction and Bioproducts
- Industrial Biotechnology Diagnostics (incl. Biosensors)
- Industrial Microbiology (incl. Biofeedstocks)
- Industrial Molecular Engineering of Nucleic Acids and Proteins
- Industrial Biotechnology not elsewhere classified
- Medical Biotechnology Diagnostics (incl. Biosensors)
- Biological Engineering
- Regenerative Medicine (incl. Stem Cells and Tissue Engineering)
- Medical Biotechnology not elsewhere classified
- Agricultural Marine Biotechnology
- Biomaterials
- Biomechanical Engineering
- Biotechnology
- Biomarkers
- Biomedical Engineering not elsewhere classified
- Genetic Engineering
- Synthetic Biology
- Bioremediation
- Medical Molecular Engineering of Nucleic Acids and Proteins